Dataset from A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate Efficacy and Safety of Finerenone on the Reduction of Cardiovascular Morbidity and Mortality in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease in Addition to Standard of Care.

The purpose of this study was to evaluate whether oral finerenone (study drug), in addition
to standard daily therapy, is effective and safe in treating patients with type 2 diabetes
mellitus and diabetic kidney disease, when compared to a placebo.